Staging MR lymphangiography of the axilla for early breast cancer: Cost-effectiveness analysis

American Journal of Roentgenology

Volumn 191, Issue 5, 2008, Pages 1308-1319

  Pandharipande, Pari V ^a   Harisinghani, Mukesh G ^a   Ozanne, Elissa M ^a   Specht, Michelle C ^a   Hur, Chin ^a   Lee, Janie M ^a   Gazelle, G Scott ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Breast cancer; Cost effectiveness analysis; MR lymphangiography; Sentinel lymph node biopsy

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; ARTICLE; AXILLA; BREAST CANCER; BREAST SURGERY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HUMAN; HUMAN TISSUE; LIFE EXPECTANCY; LYMPHANGIOGRAPHY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SENTINEL LYMPH NODE BIOPSY; TREATMENT OUTCOME;

AXILLA; BOSTON; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; LYMPHATIC METASTASIS; LYMPHOGRAPHY; MAGNETIC RESONANCE IMAGING; SENTINEL LYMPH NODE BIOPSY;

EID: 55549091394     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.07.3861     Document Type: Article

References (57)

1. American Cancer Society. Cancer facts and figures 2007. Atlanta, GA: American Cancer Society, 2007
2. Conn CA, McMasters KM, Edwards MJ, Martin RC. Acceptance of sentinel lymph node biopsy of the breast by all general surgeons in Kentucky. Breast J 2005; 11:231-235
3. Torrenga H, Fabry H, van der Sijp JR, van Diest PJ, Pijpers R, Meijer S. Omitting axillary lymph node dissection in sentinel node negative breast cancer patients is safe: a long term follow-up analysis. J Surg Oncol 2004; 88:4-7
4. Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003; 349:546-553
5. Burak WE, Hollenbeck ST, Zervos EE, Hock KL, Kemp LC, Young DC. Sentinel lymph node biopsy results in less postoperative morbidity compared with axillary lymph node dissection for breast cancer. Am J Surg 2002; 183:23-27
6. Cody HS 3rd. Current surgical management of breast cancer. Curr Opin Obstet Gynecol 2002; 14:45-52
7. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ; 10th St. Gallen conference. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18:1133-1144 [Erratum in Ann Oncol 2007; 18:2043-2044]
8. Martin RC 2nd, Chagpar A, Scoggins CR, et al. Clinicopathologic factors associated with false-negative sentinel lymph-node biopsy in breast cancer. Ann Surg 2005; 241:1005-1012
9. Gemignani ML, Cody HS 3rd, Fey JV, Tran KN, Venkatraman E, Borgen PI. Impact of sentinel lymph node mapping on relative charges in patients with early-stage breast cancer. Ann Surg Oncol 2000; 7:575-580
10. Ronka R, Smitten K, Sintonen H, et al. The impact of sentinel node biopsy and axillary staging strategy on hospital costs. Ann Oncol 2004; 15:88-94
11. Harada T, Tanigawa N, Matsuki M, Nohara T, Narabayashi I. Evaluation of lymph node metastases of breast cancer using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. Eur J Radiol 2007; 63:401-407
12. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymphnode metastases in prostate cancer. N Engl J Med 2003; 348:2491-2499 [Erratum in N Engl J Med 2003; 349:1010]
13. Harisinghani MG, Weissleder R. Sensitive, noninvasive detection of lymph node metastases. PLoS Med 2004; 1:e66
14. Memarsadeghi M, Riedl CC, Kaneider A, et al. Axillary lymph node metastases in patients with breast carcinomas: assessment with nonenhanced versus USPIO-enhanced MR imaging. Radiology 2006; 241:367-377
15. Michel SC, Keller TM, Frohlich JM, et al. Preoperative breast cancer staging: MR imaging of the axilla with ultrasmall superparamagnetic iron oxide enhancement. Radiology 2002; 225:527-536
16. Stadnik TW, Everaert H, Makkat S, Sacré R, Lamote J, Bourgain C. Breast imaging. Preoperative breast cancer staging: comparison of USPIO-enhanced MR imaging and 18F-fluorodeoxyglucose (FDC) positron emission tomography (PET) imaging for axillary lymph node staging - initial findings. Eur Radiol 2006; 16:2153-2160
17. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996; 276:1253-1258
18. Surveillance, Epidemiology, and End Results (SEER) Program Website. www.seer.cancer.gov. SEER*Stat Database: Incidence-SEER 9 Regs Limited-Use, Nov 2006 Sub (1973-2004), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on November 2006 submission
19. Silverstein MJ, Skinner KA, Lomis TJ. Predicting axillary nodal positivity in 2282 patients with breast carcinoma. World J Surg 2001; 25:767-772
20. Gray RJ, Pockaj BA, Conley CR. Sentinel lymph node metastases detected by immunohistochemistry only do not mandate complete axillary lymph node dissection in breast cancer. Ann Surg Oncol 2004; 11:1056-1060
21. Littenberg B, Moses LE. Estimating diagnostic accuracy from multiple conflicting reports: a new meta-analytic method. Med Decis Making 1993; 13:313-321
22. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making 1983; 3:419-458
23. Nowak AK, Wilcken NR, Stockler MR, Hamilton A, Ghersi D. Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. Lancet Oncol 2004; 5:372-380
24. Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001; 19:980-991
25. Arias E. United States life tables, 2001: national vital statistics reports. Hyattsville, MD: National Cancer Center for Health Statistics, 2004:52
26. Adjuvant! Online. Decision making tools for health care professionals. https://www.adjuvantonline.com/index.jsp. Accessed January, 2008
27. Olivotto IA, Bajdik CD, Ravdin PM, et al. Population-based validation of the prognostic model Adjuvant! for early breast cancer. J Clin Oncol 2005; 23:2716-2725
28. Hillner BE, Desch CE, Carlson RW, Smith TJ, Esserman L, Bear HD. Trade-offs between survival and breast preservation for three initial treatments of ductal carcinoma-in-situ of the breast. J Clin Oncol 1996; 14:70-77
29. Orr RK. The impact of prophylactic axillary node dissection on breast cancer survival: a Bayesian meta-analysis. Ann Surg Oncol 1999; 6:109-116
30. Orr RK, Col NF, Kuntz KM. A cost-effectiveness analysis of axillary node dissection in postmenopausal women with estrogen receptor-positive breast cancer and clinically negative axillary nodes. Surgery 1999; 126:568-576
31. de Haes JC, de Koning HJ, van Oortmarssen GJ, van Agt HM, de Bruyn AE, van Der Maas PJ. The impact of a breast cancer screening programme on quality-adjusted life-years. Int J Cancer 1991; 49:538-544
32. de Koning HJ, van Ineveld BM, van Oortmarssen GJ, et al. Breast cancer screening and cost-effectiveness: policy alternatives, quality of life considerations and the possible impact of uncertain factors. Int J Cancer 1991; 49:531-537
33. Hillner BE, Smith TJ, Desch CE. Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer: estimates using decision analysis while awaiting clinical trial results. JAMA 1992; 267:2055-2061
34. Hayman JA, Fairclough DL, Harris JR, Weeks JC. Patient preferences concerning the trade-off between the risks and benefits of routine radiation therapy after conservative surgery for early-stage breast cancer. J Clin Oncol 1997; 15:1252-1260
35. Malin JL, Keeler E, Wang C, Brook R. Using cost-effectiveness analysis to define a breast cancer benefits package for the uninsured. Breast Cancer Res Treat 2002; 74:143-153
36. Red book 2006. Montvale, NJ: Medical Economics, 2006:577 (paclitaxel), 668 (tamoxifen)
37. Ozanne EM, Esserman LJ. Evaluation of breast cancer risk assessment techniques: a cost-effectiveness analysis. Cancer Epidemiol Biomarkers Prev 2004; 13:2043-2052
38. Taplin SH, Barlow W, Urban N, et al. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst 1995; 87:417-426
39. Winkelmayer WC, Weinstein MC, Mittleman MA, Glynn RJ, Pliskin JS. Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making 2002; 22:417-430
40. Goldman L. Cost-effectiveness in a flat world: can ICDs help the United States get rhythm? N Engl J Med 2005; 353:1513-1515
41. Earle CC, Chapman RH, Baker CS, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol 2000; 18:3302-3317
42. Gillick MR. Medicare coverage for technological innovations: time for new criteria? N Engl J Med 2004; 350:2199-2203
43. Sloka JS, Hollett PD, Mathews M. Cost-effectiveness of positron emission tomography in breast cancer. Mol Imaging Biol 2005; 7:351-360
44. Bietendorf J. FDG PET reimbursement. J Nucl Med Technol 2004; 32:33-38
45. Sloka JS, Hollett PD, Mathews M. A quantitative review of the use of FDG-PET in the axillary staging of breast cancer. Med Sci Monit 2007; 13:RA37-RA46
46. Anzai Y, Piccoli CW, Outwater EK, et al. Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: phase III safety and efficacy study. Radiology 2003; 228: 777-788
47. Lucci A, McCall LM, Beitsch PD, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol 2007; 25:3657-3663
48. Froberg DG, Kane RL. Methodology for measuring health-state preferences. Part II. Scaling methods. J Clin Epidemiol 1989; 42:459-471
49. Froberg DG, Kane RL. Methodology for measuring health-state preferences. Part I. Measurement strategies. J Clin Epidemiol 1989; 42:345-354
50. Buzdar AU, Coombes RC, Goss PE, Winer EP. Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. Cancer 2008; 112:700-709
51. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-1717
52. Sun Y, Goodison S, Li J, Liu L, Farmerie W. Improved breast cancer prognosis through the combination of clinical and genetic markers. Bioinformatics 2007; 23:30-37
53. Tsumagari K, Chijiiwa K, Nagai H, et al. Postoperative prognosis of node-negative breast cancers predicted by gene-expression profiling on a cDNA microarray of 25,344 genes. Breast Cancer 2005; 12:166-177
54. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998; 352:930-942
55. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351:1451-1467
56. Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the "DEALE"). Part I. Validation of the method. Am J Med 1982; 73:883-888
57. Beck JR, Pauker SG, Gottlieb JE, Klein K, Kassirer JP. A convenient approximation of life expectancy (the "DEALE"). Part II. Use in medical decision-making. Am J Med 1982; 73:889-897